2018 ACVIM Forum Research Abstract Program: Seattle, Washington, June 14 - 15, 2018

Twenty-five different breeds were represented. Ages ranged from 0.7-14 years (median 8.0 years). Fifty-two percent were female spayed and 43% were male castrated. The most common treatment side-effects were gastrointestinal signs, which ranged from mild inappetence to vomiting and diarrhea in 44% (22/50) and gingival hyperplasia in 26% (13/50). Seventy six percent (38/50) achieved remission with a median time to remission of 2 months (0.75-12 months). The median dose at the time of remission was 7.8 mg/kg/ day (1.5-12.7 mg/kg/day). No association was found between prognostic factors and remission with the exception of hypoalbuminemia. There was an increased likelihood of remission (p < 0.05) and a decreased time to remission in dogs with hypoalbuminemia (p < 0.05).